CT-guided interstitial high-dose-rate brachytherapy of lung malignancies: Efficacy and Safety

CT-guided interstitial high-dose-rate brachytherapy of lung malignancies: Efficacy and Safety - AL Lung

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011204

Enrollment

174

Registered

2017-01-10

Start date

2016-12-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34 C78.0

Interventions

Group 1: 174 patients that have been treated between March 2006 and January 2015 will be included in the retrospective evaluation. Patients with secondary or primary lung malignancies and confirmed tr

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with inoperable lung tumors where HDR-brachytherapy is an adequate treatment option and who have been treated in the period from March 2006 to January 2015.

Exclusion criteria

Exclusion criteria: Treatment of recurring tumor that has already been treated with brachytherapy

Design outcomes

Primary

Measure	Time frame
Local response after CT-guided brachytherapy of lung malignancies. Following RECIST criteria, local response is defined by shrinking of target lesions. Evaluation is based on available follow-up CT scans.	—

Secondary

Measure	Time frame
Progression-free survival (PFS), Overall Survival (OS), Safety	—

Countries

Germany

Contacts

Public ContactChristel Besseler

Klinik für Radiologie und Nuklearmedizin

christel.besseler@ed.ovgu.de+49-391-6713071

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026